Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasquinimod in advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas
2012-002326-75Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tasquinimod in hepatocellular carcinoma (HCC), ovarian cancer, renal cell carcinoma (RCC) and 1 more (4 cohorts), sponsored by Ipsen. Primary endpoint: Progression-free survival rate. Started Jul 2012; status: completed.
02
Drugs
tasquinimod
03
Conditions
hepatocellular carcinoma (HCC)ovarian cancerrenal cell carcinoma (RCC)gastric adenocarcinoma
Beyond the preview
Go deeper on 2012-002326-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002326-75.